JPMorgan Chase & Co. Sells 98,640 Shares of DENTSPLY SIRONA Inc. $XRAY

JPMorgan Chase & Co. reduced its position in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 19.1% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 416,856 shares of the medical instruments supplier’s stock after selling 98,640 shares during the quarter. JPMorgan Chase & Co.’s holdings in DENTSPLY SIRONA were worth $5,290,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of DENTSPLY SIRONA in the first quarter valued at $26,000. Huntington National Bank grew its stake in shares of DENTSPLY SIRONA by 292.9% during the 3rd quarter. Huntington National Bank now owns 2,786 shares of the medical instruments supplier’s stock worth $35,000 after acquiring an additional 2,077 shares during the period. Caitong International Asset Management Co. Ltd grew its stake in shares of DENTSPLY SIRONA by 337.9% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,750 shares of the medical instruments supplier’s stock worth $35,000 after acquiring an additional 2,122 shares during the period. True Wealth Design LLC increased its holdings in DENTSPLY SIRONA by 49.7% in the 3rd quarter. True Wealth Design LLC now owns 3,557 shares of the medical instruments supplier’s stock worth $45,000 after acquiring an additional 1,181 shares during the last quarter. Finally, Central Pacific Bank Trust Division raised its stake in DENTSPLY SIRONA by 100.0% in the 3rd quarter. Central Pacific Bank Trust Division now owns 4,000 shares of the medical instruments supplier’s stock valued at $51,000 after acquiring an additional 2,000 shares during the period. 95.70% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Robert W. Baird upped their price objective on shares of DENTSPLY SIRONA from $12.00 to $14.00 and gave the company a “neutral” rating in a report on Friday, February 27th. UBS Group reduced their target price on shares of DENTSPLY SIRONA from $17.00 to $16.00 and set a “buy” rating for the company in a research note on Tuesday, February 3rd. Barrington Research upped their price target on shares of DENTSPLY SIRONA from $14.00 to $17.00 and gave the company an “outperform” rating in a research note on Monday, March 2nd. Barclays started coverage on shares of DENTSPLY SIRONA in a report on Monday, December 8th. They issued an “underweight” rating and a $12.00 price objective for the company. Finally, Wells Fargo & Company lifted their price objective on shares of DENTSPLY SIRONA from $12.00 to $13.00 and gave the company an “equal weight” rating in a research note on Friday, February 27th. Three analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $14.42.

Insider Buying and Selling

In other news, Director Gregory T. Lucier bought 27,555 shares of the stock in a transaction on Monday, March 2nd. The shares were acquired at an average cost of $14.24 per share, for a total transaction of $392,383.20. Following the purchase, the director directly owned 27,555 shares of the company’s stock, valued at $392,383.20. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director James D. Forbes bought 5,000 shares of the stock in a transaction on Monday, March 9th. The stock was purchased at an average price of $12.48 per share, for a total transaction of $62,400.00. Following the completion of the purchase, the director directly owned 10,000 shares in the company, valued at approximately $124,800. This represents a 100.00% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought 70,000 shares of company stock valued at $956,437 over the last 90 days. 0.50% of the stock is owned by company insiders.

DENTSPLY SIRONA Stock Performance

Shares of XRAY opened at $11.66 on Thursday. DENTSPLY SIRONA Inc. has a 52-week low of $9.85 and a 52-week high of $17.18. The stock’s 50-day simple moving average is $12.52 and its 200 day simple moving average is $12.16. The company has a debt-to-equity ratio of 1.50, a quick ratio of 1.03 and a current ratio of 1.51. The stock has a market capitalization of $2.33 billion, a price-to-earnings ratio of -3.89, a price-to-earnings-growth ratio of 1.36 and a beta of 0.99.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its earnings results on Thursday, February 26th. The medical instruments supplier reported $0.27 earnings per share for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). DENTSPLY SIRONA had a negative net margin of 16.25% and a positive return on equity of 18.85%. The company had revenue of $961.00 million for the quarter, compared to analysts’ expectations of $926.40 million. During the same period in the previous year, the firm earned $0.26 EPS. The firm’s quarterly revenue was up 6.2% compared to the same quarter last year. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Research analysts forecast that DENTSPLY SIRONA Inc. will post 1.84 EPS for the current fiscal year.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.